DEPARTMENT OF THORACIC & CARDIOVASCULAR SURGERY ST. PAUL’S HOSPITAL THE CATHOLIC UNIVERSITY OF KOREA CHAN BEOM PARK SURGICAL STRATEGRY FOR CABG WITH ASSOCIATED.

DEPARTMENT OF THORACIC &

CARDIOVASCULAR SURGERY

ST. PAUL’S HOSPITAL

THE CATHOLIC UNIVERSITY OF KOREA

CHAN BEOM PARK

SURGICAL STRATEGRY FOR SURGICAL STRATEGRY FOR

CABG WITH ASSOCIATED CABG WITH ASSOCIATED

VALVE SURGERYVALVE SURGERY

대한흉부외과학회 제 24 차 춘계학술대회

Combinded Procedures. In: Surgery of Coronary artery disease, Wheatley DJ. London: Arnold 2003, 326-33.

STS Database STS Database Jan 1992-Dec Jan 1992-Dec 20012001

CABGCABG75.2%75.2%

AVR+CABG

MVR+CABG

AVR+MVR

MV Repair

MV Repair+CABG

1.37%0.86%0.92%

[ http://www.ktcs.or.kr/ ]

대한흉부외과학회 대한흉부외과학회 Database Database 2001-2001-20052005

2527 25412409 2420 2347

2001 2002 2003 2004 2005

ValveCABGCABG+Valve

21762340

123 147 145 185 213

CABG with Aortic Valve diseaseCABG with Aortic Valve disease

AV Replace

AV Replace+CABG

Procedure year

1994 1995 1996 1997 1998 1999 2000 2001

Combinded Procedures. In: Surgery of Coronary artery disease, Wheatley DJ. London: Arnold 2003, 326-33.

Operative Mortality for AVR Operative Mortality for AVR with with or or

withoutwithout CABG CABG –STS Database-–STS Database-

Lytle BW. JTCS 1988;95:402-14

Long-term Survival after AVR with Long-term Survival after AVR with CABGCABG

Major cardiac event: reoperation, permanent neurologic event, MI, bleeding, endocarditis, hospitalization for CHF, NYHA III/IV Sx, death

Jones EL. ATS 1994;58:378-85

No CAD(N=1396)Mean Age 56yrs

CAD(N=883)Mean Age 67yrs

Hosp. Mortality

p<0.0001

Time (Yrs)

0 5 10 15 20

Survival after AVR with/without Survival after AVR with/without CABGCABG

Stewart BF. JACC 1997;29:630-4

VariableP

valueOdds Ratio

95% Confidence Limits

Age <0.001 2.18* 2.15,2.20

Male gender

<0.001 2.03 1.7,2.5

Lp(a) <0.001 1.23† 1.14,1.32

Height(cm)

0.001 0.84‡ 0.75,0.93

HBP 0.002 1.23 1.1,1.4

Smoking 0.006 1.35 1.1,1.7

LDLc(mg/dl)

0.008 1.12† 1.03,1.23*±75th vs 25th percentile. †±10-year increase. ‡±10unit increase. LDLc=low density lipoprotein cholesterol; Lp(a)=lipoprotein(a)

Clinical Factors associated with Clinical Factors associated with Calcific Calcific

Aortic Valve diseaseAortic Valve disease

Pohle K. Circulation 2001;104:1927-32

AV Calcification associated with AV Calcification associated with Coronary AtherosclerosisCoronary Atherosclerosis

Atherosclerotic Changes in Aortic Atherosclerotic Changes in Aortic Valves of Valves of Hypercholesterolemic RabbitsHypercholesterolemic Rabbits

Aortic Valve-Cholesterol diet

Aorta-Cholesterol diet

Aorta-Normal diet

Fiore AC. ATS 1996;61:1693-8

CABG then AVR

CABG with AVR

Mild AS >1.0cm2

26±10mmHg1.05±0.2cm2

61.3±26mmHg0.69±0.12cm2

CABG then AVR CABG/AVR

53.2±24mmHg0.73±0.21cm2

Management of Asx Mild AS during Management of Asx Mild AS during

CABGCABG

p = NS

PERCENT

0 21 3 4 5 6 7 8 9 10

Hochrein J. Am Heart J 1999;138:791-7

Mean AS gradient CABG: 25.9±11.2 (14-66) mmHg AVR/CABG: 52.5±18.9 (14-126) mmHg

Freedom from AVRFreedom from AVR (CABG)(CABG) vs AV Reopvs AV Reop (AVR/CABG)(AVR/CABG)

in Mild to Moderate AV Diseasein Mild to Moderate AV Disease

P=0.0024

AVR/CABG

Mild AS

: Mean PG< 30mmHg, and/or Valve area >1.5cm2

Moderate AS: Mean PG≥30mmHg and ≤40mmHg, and/or

Valve area >1.0 and ≤ 1.5cm2

Pereira JJ. Am J Med 2005;118:735-42

Survival after Mild/Moderate AVR Survival after Mild/Moderate AVR with CABGwith CABG

AVR-CABG

Tom JW. ATS 1998;65:1215-9

1 3 75 92 64 80 yrs

Progression of Mild AS in CABG Progression of Mild AS in CABG PatientsPatients

VariableEvent-FreeSurvivors

Progressionto Severe AS

P value

Age(yr) 61.1±9.5 60.0±9.6 NS

AS gradient (mmHg)

9.6±7.1 20.7±9.9 0.0005

Calcium score

0.8±0.7 1.3±0.7 0.06

Mobility score 0.9±0.8 1.0±0.9 NS

Rosenhek, R. Eur Heart J 2004 25:199-205

No CAD (1,3,5yr) : 98±1%, 86±3%, 74±4%

CAD (1,3,5yr) : 94±3%, 63±7%, 40±8% (p=0.0002)

Predictors of OutcomePredictors of Outcome- Calcification, AV velocity, CAD -- Calcification, AV velocity, CAD -

Smith IV WT. J Am Coll Cardiol 2004;44:1241-7

1995-2000, 1,344,100 CABG, CABG/AVR, AVR after CABG

in STS National Database

Immediate 1yr 5yr 10yr 15yr

CABG CABG/AVR

Immediate 1yr 5yr 10yr 15yr

CABG CABG/AVR

Death Event Free

65-yr-old, Peak AV Gradient 65-yr-old, Peak AV Gradient 30mmHg, Progression of AS of 30mmHg, Progression of AS of

5mmHg/Yr5mmHg/Yr

Smith IV WT. J Am Coll Cardiol 2004;44:1241-7

CABG/AVR preferred

preferredCABG

1995-2000, 1,344,100 CABG, CABG/AVR, AVR after CABG

in STS National Database

Rate of AS progression: 5mmHg/year

Should CABG undergo Concomitant Should CABG undergo Concomitant

AVRAVRin Mild or Moderate AS ?in Mild or Moderate AS ?

- A Decision Analysis Approach to the Surgical Dilemma -- A Decision Analysis Approach to the Surgical Dilemma -

Age at time of CABG

10.4. AVR in Patients Undergoing CABG

• Class I AVR is indicated in patients undergoing CABG who have severe AS who meet the criteria

for valve replacement (see Section 3.1.7). (Level of Evidence: C)

Circulation 2006;114;84-231

• Class IIa AVR is reasonable in patients undergoing CABG who have moderate AS (mean gradient 30 to

50 mmHg or Doppler velocity 3 to 4 m/sec). (Level of Evidence: B)

• Class IIb AVR may be considered in patients undergoing CABG who have mild AS (mean gradient less

than 30 mm Hg or Doppler velocity less than 3 m/sec) when there is evidence, such as moderate severe valve calcification, that progression may be rapid. (Level of Evidence: C)

ACC/AHA 2006 Guidelines for the Management

of Patient With VHD

Bauer EP. EJCTS 1996;10:248-52

Variable IMA(n=68)

SVG(n=120)

P value

Non-survivors 4(6%) 6(5%) NS

Mechanical ventilation(hours)

30±4.8 21±3.5 NS

Catecholamine support 34(50%) 67(56%) NS

CK-MB(highest value) 43±3.0 42±4.2 NS

Transfusion 30(44%) 62(52%) NS

ICU stay(days) 4.4±0.7 4.0±0.3 NS

Rethoracotomy 1(1.5%) 2(1.6%) NS

Sternal wound infection 0 1(0.8%) NS

Ustable sternum 1(1%) 0 NS

Is the Use of IMA a Predictor for Early Is the Use of IMA a Predictor for Early

Complications?Complications?

Gall S. ATS 2000;69:524-30

LAD-IMA vs LAD-SVG

p=0.0017

No LAD

LAD-SVG

LAD-IMA

Efficacy of IMA in AVR with Efficacy of IMA in AVR with

CABGCABG

Observed Survival Adjusted Survival

Karthik S. ATS 2005;80:163-9

Mean F/U Period: average 3.7yrs

Effect of LIMA-LAD in AVR with Effect of LIMA-LAD in AVR with

CABGCABG

Kobayashi KJ. ATS 2007;83:969-78

One graft

Two graft

Multiple graft

2000-2004

378 AVR-CABG at Johns Hopkins

Impact of Multiple Grafts in AVR with Impact of Multiple Grafts in AVR with

CABGCABG

P=0.91

Mean F/U Period: average 2.2±1.7yrs

Lytle BW. JTCS 1988;95:402-14

PERCENT100

BIOPROSTHESIS, n=218

MECHANICAL, n=253

Long-term Survival according to Valve Long-term Survival according to Valve Type in AVR & CABGType in AVR & CABG

Puvimanasinghe JPA. EJCTS 2003;23:688-95

AVR without CABG AVR with CABG

LE: Life Expectancy

EFLE: Event-Free Life Expectancy

11.6yr

11.2yr8.9yr

10.2yr

59-60yr 58-

Comparison of Life Expectancy & Comparison of Life Expectancy &

Event Free Life ExpectancyEvent Free Life Expectancy

Puvimanasinghe JPA. EJCTS 2003;23:688-95

• AVR without CABG: 63yrs

• AVR with CABG: 62yrs

Lifetime Risk of SVD with Lifetime Risk of SVD with

Bioprosthesis, Bioprosthesis,

Hemorrhage with Mechanical ValveHemorrhage with Mechanical Valve

LeBoutillier III M. Valvular and IHD. In: Cohn LH. Cardiac Surgery in the Adult. 2nd ED. New York: McGraw-Hill Co. 2003;1061

Operative Sequences for AVR & Operative Sequences for AVR &

CABGCABG

Distal anastomosis at first

CABG with Mitral Valve diseaseCABG with Mitral Valve diseaseCABG with Mitral Valve diseaseCABG with Mitral Valve disease

Combinded Procedures. In: Surgery of Coronary artery disease, Wheatley DJ. London: Arnold 2003, 326-33

Procedure year

1994 1995 1996 1997 1998 1999 2000 2001

MV Replace

MV Replace+CABG

Operative Mortality for MVR Operative Mortality for MVR with/without CABGwith/without CABG –STS Database-–STS Database-

Lytle BW. Circulation 1985;71:1179-90

Long-term Survival after MVR & Long-term Survival after MVR &

CABGCABG

Czer LSC. Circulation 1984;70 (suppl I):I-198-I-207

1969-1982, 419 MVR patients No CAD: 216

CAD with CABG: 179

CAD without CABG: 24

Unmatched Cohort Matched Cohort

NO CAD

CAD and CABG

CAD, No CABG

P=0.07

P<0.05

Survival after MVR with or without Survival after MVR with or without

CADCAD

No CAD vs CABG P=0.07

CABG vs CAD, No CABG P<0.05

NO CAD

CAD and CABG

CAD, No CABG

P<0.05

Survival after MVRSurvival after MVR & Incidental CAD & Incidental CAD (Rheumatic)(Rheumatic)

Jones EL. ATS 1994;58:378-85

Hosp. Mortality5.6%

14.2% No CAD(N=934)Mean Age 54yrs

CAD(N=340)Mean Age 64yrs

p<0.0001

Time (Yrs)

0 102 4 6 8

Survival after MVR with/without Survival after MVR with/without

CADCAD

Lytle BW. Circulation 1985;71:1179-90

P=0.02

Survival of MVR with CABGSurvival of MVR with CABG based on Etiology of MVDbased on Etiology of MVD

Rheumatic

P<0.01

Ischemic

Survival according to Survival according to

EtiologyEtiology

Seipelt RG. EJCTS 2001;20:270-5

Hospital Mortality Ischemic: 19.5% Rheumatic 7.9% Degenerative: 2.4%

Jan 1984- Dec 1997262 MVR with CABG

Survival Rate

Degenerative MVDIschemic MVD

Rheumatic MVD

Survival of Combined MVD & Survival of Combined MVD &

CABGCABG based on Etiology of MVDbased on Etiology of MVD

0 2 4 6 8 10Years

Gillinov AM. ATS 2005;80:811-9

Unadjusted Survival Adjusted Survival

Ischemic MR Degenerative MR with CAD

LV dysfunction → MR MR ± LV dysfunction

p<0.0001 p>0.9

One disease Two disease

Degenerative MR with CAD vs Ischemic MR

Gillinov AM. ATS 2005;80:811-9

Ischemic MR

Homogeneous Survival Curve

Degenerative MR

Inhomogeneous Survival Curve

Severity of CAD and LV dysfunction

impact on Survival

Degenerative MR with CAD vs Ischemic MR

Univariate

p value

Multivariate

p value

Age > 72yrs 0.0001 < 0.0001

EF < 35% < 0.0001 0.0039

Replacement 0.037 0.019

3-vessel CAD 0.0001 0.0086

Dismissal MR > 2 0.019 0.042

NYHA III/IV 0.0002 0.072

Ischemic 0.0036 0.21

Dahlberg PS. ATS 2003;76:1539-48

Late Outcome of MV Surgery & Late Outcome of MV Surgery &

CABGCABG

Overall Survival for Repair and Replace

for association of CABG

Akins CW. ATS 1994;58:668-76

Thourani VH. Circulation 2003;108:298-304

No Survival Benefit in Mitral Repair and CABG

Matched Case-Control Study

Enrinquez-Sarano M. Circulation 1995;91:1022-8

Overall Survival for Repair and Replace

for association of CABG

With CABG Without CABG

RepairReplacement

P=0.0008P=0.0002

74±8%

34±8%

73±7%

61±5%

• Jan 1980-Dec 1989, 409 Organic MR (except Ischemic MR)• Repair 195, Replacement 214

Enriquez-Sarano M. Circulation 2003;108:253-6

Survival for Repair and Replacement

for concomitant CABG

P<0.01

•1980- 1995, 1344 Pure MR • Repair 897, Replacement 447

Gillinov AM. JTCS 2003;125:1350-62

Repair vs Replacement for Repair vs Replacement for

Degenerative Degenerative

MVD with IHDMVD with IHD

• 1973- 1999, 679 Degenerative MR with CABG• Repair 447, Replacement 232

Gillinov AM. JTCS 2003;125:1350-62

Survival benefit of

Repair

Repair vs Replacement for Degenerative MVD with IHD

Operative Operative

SequencesSequencesfor MVR & CABGfor MVR & CABG

LeBoutillier III M. Valvular and IHD. In: Cohn LH. Cardiac Surgery in the Adult. 2nd ED. New York: McGraw-Hill Co. 2003;1066

Experiences in St. Paul’s Experiences in St. Paul’s

HospitalHospital

AV Surgery MV SurgeryIncidence 9/369 (2.4%) 12/369 (3.3%)

Sex(M:F) 5:4 6:6

Age 67.2±6.9 63.6±7.9

Etiology

Degenerative 7 1

Rheumatic 1 3

Congenital 1

Ischemic (Functional) 7

Ischemic (PM rupture) 1

Number of bypass graft 1.4±0.7 2.2±0.8

LIMA 8(88.9%) 9(75%)

Experiences in St. Paul’s Experiences in St. Paul’s

HospitalHospital

AV Surgery MV SurgeryCPB time (min) 229.0±65.9 283.1±93.9

ACC time (min) 182.6±50.0 198.9±45.7

Complications

Mediastinitis 1

Sudden cardiac arrest 1

Pneumonia 1

Hepatic failure 1

Bleeding 2

Low cardiac output 3

Operative mortality 1/9 (11.1%) 2/12 (16.7%)

DEPARTMENT OF THORACIC & CARDIOVASCULAR SURGERY ST. PAUL’S HOSPITAL THE CATHOLIC UNIVERSITY OF KOREA CHAN BEOM PARK SURGICAL STRATEGRY FOR CABG WITH ASSOCIATED.

Documents

Stroke After PCI vs. CABG (All Pts. and Left Main...

Surgical Treatment for Ischemic Heart Failure (STICH) Trial:...

164.115.44.223164.115.44.223/contents/pdf/songkran.pdf ·.....

RMT in CABG

2011 CABG Guidelines

Presenter Lee Beom -Jin

CABG Bsc nursing

CABG PPT KS

Which CTO should be treated by PCI or CABG The specific...

California CABG Outcomes Reporting Program … California...

Ptca vs cabg

CABG (Hebrew)

Cabg Guideline

Baheti CABG Pain

Laporan Kasus CABG ICCU

CABG VS PCI